1vr1: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
New page: left|200px<br /> <applet load="1vr1" size="450" color="white" frame="true" align="right" spinBox="true" caption="1vr1, resolution 1.9Å" /> '''Specifity for Plasmi...
 
No edit summary
 
(17 intermediate revisions by the same user not shown)
Line 1: Line 1:
[[Image:1vr1.gif|left|200px]]<br />
<applet load="1vr1" size="450" color="white" frame="true" align="right" spinBox="true"
caption="1vr1, resolution 1.9&Aring;" />
'''Specifity for Plasminogen Activator Inhibitor-1'''<br />


==Overview==
==Specifity for Plasminogen Activator Inhibitor-1==
Substitution of the native variable region-1 (VR1/37-loop) of thrombin by, the corresponding VR1 of tissue-type plasminogen activator, (thrombin-VR1(tPA)) increases the rate of inhibition by plasminogen, activator inhibitor type 1 (PAI-1) by three orders of magnitude, and is, thus sufficient to confer PAI-1 specificity to a heterologous serine, protease. A structural and kinetical approach to establish the function of, the VR1 loop of t-PA in the context of the thrombin-VR1(tPA) variant is, described. The crystal structure of thrombin-VR1(tPA) was resolved and, showed a conserved overall alpha-thrombin structure, but a partially, disordered VR1 loop as also reported for t-PA. The contribution of a, prominent charge substitution close to the active site was studied using, charge neutralization variants thrombin-E39Q(c39) and, thrombin-VR1(tPA)-R304Q(c39), resulting in only fourfold changes in the, PAI-1 inhibition rate. Surface plasmon resonance revealed that the, affinity of initial reversible complex formation between PAI-1 and, catalytically inactive Ser195--&gt;Ala variants of thrombin and, thrombin-VR1(tPA) is only increased fivefold, i.e. KD is 652 and 128 nM, for thrombin-S195A and thrombin-S195A-VR1(tPA), respectively. We, established that the partition ratio of the suicide substrate reaction, between the proteases and PAI-1 was largely unaffected in any variant, studied. Hirugen allosterically decreases the rate of thrombin inhibition, by PAI-1 2.5-fold and of thrombin-VR1(tPA) 20-fold, by interfering with a, unimolecular step in the reaction, not by decreasing initial complex, formation or by altering the stoichiometry. Finally, kinetic modeling, demonstrated that acylation is the rate-limiting step in thrombin, inhibition by PAI-1 (k approximately 10(-3) s(-1)) and this kinetic block, is alleviated by the introduction of the tPA-VR1 into thrombin (k&gt;1, s(-1)). We propose that the length, flexibility and different charge, architecture of the VR1 loop of t-PA invoke an induced fit of the reactive, center loop of PAI-1, thereby enhancing the rate of acylation in the, Michaelis complex between thrombin-VR1(t-PA) and PAI-1 by more than two, orders of magnitude.
<StructureSection load='1vr1' size='340' side='right'caption='[[1vr1]], [[Resolution|resolution]] 1.90&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[1vr1]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Hirudo_medicinalis Hirudo medicinalis] and [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1VR1 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=1VR1 FirstGlance]. <br>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.9&#8491;</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=TYS:O-SULFO-L-TYROSINE'>TYS</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=1vr1 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1vr1 OCA], [https://pdbe.org/1vr1 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=1vr1 RCSB], [https://www.ebi.ac.uk/pdbsum/1vr1 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=1vr1 ProSAT]</span></td></tr>
</table>
== Function ==
[https://www.uniprot.org/uniprot/HIRV1_HIRME HIRV1_HIRME] Hirudin is a potent thrombin-specific protease inhibitor. It forms a stable non-covalent complex with alpha-thrombin, thereby abolishing its ability to cleave fibrinogen.<ref>PMID:17585879</ref>
== Evolutionary Conservation ==
[[Image:Consurf_key_small.gif|200px|right]]
Check<jmol>
  <jmolCheckbox>
    <scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/vr/1vr1_consurf.spt"</scriptWhenChecked>
    <scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview03.spt</scriptWhenUnchecked>
    <text>to colour the structure by Evolutionary Conservation</text>
  </jmolCheckbox>
</jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=1vr1 ConSurf].
<div style="clear:both"></div>
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Substitution of the native variable region-1 (VR1/37-loop) of thrombin by the corresponding VR1 of tissue-type plasminogen activator (thrombin-VR1(tPA)) increases the rate of inhibition by plasminogen activator inhibitor type 1 (PAI-1) by three orders of magnitude, and is thus sufficient to confer PAI-1 specificity to a heterologous serine protease. A structural and kinetical approach to establish the function of the VR1 loop of t-PA in the context of the thrombin-VR1(tPA) variant is described. The crystal structure of thrombin-VR1(tPA) was resolved and showed a conserved overall alpha-thrombin structure, but a partially disordered VR1 loop as also reported for t-PA. The contribution of a prominent charge substitution close to the active site was studied using charge neutralization variants thrombin-E39Q(c39) and thrombin-VR1(tPA)-R304Q(c39), resulting in only fourfold changes in the PAI-1 inhibition rate. Surface plasmon resonance revealed that the affinity of initial reversible complex formation between PAI-1 and catalytically inactive Ser195--&gt;Ala variants of thrombin and thrombin-VR1(tPA) is only increased fivefold, i.e. KD is 652 and 128 nM for thrombin-S195A and thrombin-S195A-VR1(tPA), respectively. We established that the partition ratio of the suicide substrate reaction between the proteases and PAI-1 was largely unaffected in any variant studied. Hirugen allosterically decreases the rate of thrombin inhibition by PAI-1 2.5-fold and of thrombin-VR1(tPA) 20-fold, by interfering with a unimolecular step in the reaction, not by decreasing initial complex formation or by altering the stoichiometry. Finally, kinetic modeling demonstrated that acylation is the rate-limiting step in thrombin inhibition by PAI-1 (k approximately 10(-3) s(-1)) and this kinetic block is alleviated by the introduction of the tPA-VR1 into thrombin (k&gt;1 s(-1)). We propose that the length, flexibility and different charge architecture of the VR1 loop of t-PA invoke an induced fit of the reactive center loop of PAI-1, thereby enhancing the rate of acylation in the Michaelis complex between thrombin-VR1(t-PA) and PAI-1 by more than two orders of magnitude.


==Disease==
The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.,Dekker RJ, Eichinger A, Stoop AA, Bode W, Pannekoek H, Horrevoets AJ J Mol Biol. 1999 Oct 29;293(3):613-27. PMID:10543954<ref>PMID:10543954</ref>
Known diseases associated with this structure: Dysprothrombinemia OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=176930 176930]], Hyperprothrombinemia OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=176930 176930]], Hypoprothrombinemia OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=176930 176930]]


==About this Structure==
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
1VR1 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1VR1 OCA].
</div>
<div class="pdbe-citations 1vr1" style="background-color:#fffaf0;"></div>


==Reference==
==See Also==
The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop., Dekker RJ, Eichinger A, Stoop AA, Bode W, Pannekoek H, Horrevoets AJ, J Mol Biol. 1999 Oct 29;293(3):613-27. PMID:[http://ispc.weizmann.ac.il//pmbin/getpm?pmid=10543954 10543954]
*[[Hirudin 3D structures|Hirudin 3D structures]]
*[[Thrombin 3D Structures|Thrombin 3D Structures]]
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Hirudo medicinalis]]
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
[[Category: Single protein]]
[[Category: Large Structures]]
[[Category: Bode, W.]]
[[Category: Bode W]]
[[Category: Dekker, R.J.]]
[[Category: Dekker RJ]]
[[Category: Eichinger, A.]]
[[Category: Eichinger A]]
[[Category: Horrevoets, A.J.G.]]
[[Category: Horrevoets AJG]]
[[Category: Pannekoek, H.]]
[[Category: Pannekoek H]]
[[Category: Stoop, A.A.]]
[[Category: Stoop AA]]
[[Category: thrombin]]
 
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 19:44:40 2007''

Latest revision as of 10:29, 9 October 2024

Specifity for Plasminogen Activator Inhibitor-1Specifity for Plasminogen Activator Inhibitor-1

Structural highlights

1vr1 is a 3 chain structure with sequence from Hirudo medicinalis and Homo sapiens. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Method:X-ray diffraction, Resolution 1.9Å
Ligands:
Resources:FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Function

HIRV1_HIRME Hirudin is a potent thrombin-specific protease inhibitor. It forms a stable non-covalent complex with alpha-thrombin, thereby abolishing its ability to cleave fibrinogen.[1]

Evolutionary Conservation

Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf.

Publication Abstract from PubMed

Substitution of the native variable region-1 (VR1/37-loop) of thrombin by the corresponding VR1 of tissue-type plasminogen activator (thrombin-VR1(tPA)) increases the rate of inhibition by plasminogen activator inhibitor type 1 (PAI-1) by three orders of magnitude, and is thus sufficient to confer PAI-1 specificity to a heterologous serine protease. A structural and kinetical approach to establish the function of the VR1 loop of t-PA in the context of the thrombin-VR1(tPA) variant is described. The crystal structure of thrombin-VR1(tPA) was resolved and showed a conserved overall alpha-thrombin structure, but a partially disordered VR1 loop as also reported for t-PA. The contribution of a prominent charge substitution close to the active site was studied using charge neutralization variants thrombin-E39Q(c39) and thrombin-VR1(tPA)-R304Q(c39), resulting in only fourfold changes in the PAI-1 inhibition rate. Surface plasmon resonance revealed that the affinity of initial reversible complex formation between PAI-1 and catalytically inactive Ser195-->Ala variants of thrombin and thrombin-VR1(tPA) is only increased fivefold, i.e. KD is 652 and 128 nM for thrombin-S195A and thrombin-S195A-VR1(tPA), respectively. We established that the partition ratio of the suicide substrate reaction between the proteases and PAI-1 was largely unaffected in any variant studied. Hirugen allosterically decreases the rate of thrombin inhibition by PAI-1 2.5-fold and of thrombin-VR1(tPA) 20-fold, by interfering with a unimolecular step in the reaction, not by decreasing initial complex formation or by altering the stoichiometry. Finally, kinetic modeling demonstrated that acylation is the rate-limiting step in thrombin inhibition by PAI-1 (k approximately 10(-3) s(-1)) and this kinetic block is alleviated by the introduction of the tPA-VR1 into thrombin (k>1 s(-1)). We propose that the length, flexibility and different charge architecture of the VR1 loop of t-PA invoke an induced fit of the reactive center loop of PAI-1, thereby enhancing the rate of acylation in the Michaelis complex between thrombin-VR1(t-PA) and PAI-1 by more than two orders of magnitude.

The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.,Dekker RJ, Eichinger A, Stoop AA, Bode W, Pannekoek H, Horrevoets AJ J Mol Biol. 1999 Oct 29;293(3):613-27. PMID:10543954[2]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

See Also

References

  1. Song X, Mo W, Liu X, Zhu L, Yan X, Song H, Dai L. The NMR solution structure of recombinant RGD-hirudin. Biochem Biophys Res Commun. 2007 Aug 17;360(1):103-8. Epub 2007 Jun 13. PMID:17585879 doi:10.1016/j.bbrc.2007.06.014
  2. Dekker RJ, Eichinger A, Stoop AA, Bode W, Pannekoek H, Horrevoets AJ. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop. J Mol Biol. 1999 Oct 29;293(3):613-27. PMID:10543954 doi:10.1006/jmbi.1999.3178

1vr1, resolution 1.90Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA